Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858552 | 0.79 | MTNR1A (0.31) | MTNR1AMTNR1BCLK1ALDH1A1 | |
| SCHEMBL1859874 | 0.77 | MTNR1A (0.32) | MTNR1AMTNR1B | |
| SCHEMBL1856340 | 0.74 | MTNR1A (0.34) | MTNR1AMTNR1B | |
| SCHEMBL1862227 | 0.74 | MTNR1A (0.32) | MTNR1AMTNR1BKMT2A | |
| SCHEMBL1400933 | 0.61 | MTNR1A (0.48) | MTNR1AMTNR1BALDH1A1MAPTKMT2A | |
| SCHEMBL1858295 | 0.59 | CHRM2 (0.32) | — | |
| SCHEMBL27964007 | 0.58 | ALDH1A1 (0.43) | MTNR1AMTNR1BCLK1ALDH1A1 | |
| SCHEMBL1863737 | 0.58 | MTNR1A (0.40) | MTNR1AMTNR1BALDH1A1MAPTKMT2A | |
| SCHEMBL4269765 | 0.58 | ALDH1A1 (0.48) | MTNR1AMTNR1BALDH1A1MAPTKMT2A | |
| SCHEMBL2092441 | 0.58 | NPSR1 (0.48) | MTNR1AMTNR1BALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | MTNR1A 515/4885MTNR1B 605/4885CLK1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.